I work with Medical Affairs teams, medcomms agencies, medical device, and biotech scientific teams who need clinical evidence translated into clear, accurate scientific narratives. Whether it’s a Medical Affairs deck, an advisory board summary, evidence synthesis, congress coverage, or a manuscript draft, I focus on getting the science right and the communication sharp.
My focus is on Nephro-cardiometabolic and endocrinology programs across pharma, biotech, and medcomms agencies. I bring familiarity with the therapy area landscape — GLP-1, GIP, and glucagon receptor agonists (semaglutide, tirzepatide, retatrutide, survodutide, orforglipron); SGLT2 inhibitors; MASH pharmacotherapy (FGF21 analogs, THR-β agonists, pan-PPAR agonists); heart failure with preserved and mildly reduced ejection fraction; type 2 diabetes; obesity; and broader endocrine and metabolic conditions.
This depth means your team spends less time briefing me on therapy area context and more time refining scientific strategy and message.
Five years of HCP-focused medical writing across clinical, congress, and pipeline communications. KOL interviews with academic specialists at Stanford, Harvard Medical School, NYU Langone, UC Cincinnati, Ohio State, Beth Israel Deaconess, and Providence Swedish. Conference coverage from American Diabetes Association, American Association of Clinical Endocrinology, American Society of Nephrology Kidney Week, and ENDO Week. Bylines in MedCentral, Endocrinology Advisor, Clinical Pain Advisor, Rheumatology Advisor, and Clinical Advisor.
Member: American Medical Writers Association (AMWA), European Medical Writers Association (EMWA), and Regulatory Affairs Professional Society (RAPS).
Based in Lisbon — working hours align with Central European Time for EU clients and overlap with US East Coast time for US clients.


